ESR1 and neoplasm: It was reported that although ERα-negative breast cancer has more mesenchymal characteristics and poorer prognosis than ERα-positive tumors (Tomaskovic-Crook et al., 2009), ERα-negative tumor subtypes are more likely to be benefited from DOX treatment than the other breast cancer subtypes.